MRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.

Merck’s shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly ...

The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...

The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year of age from respiratory syncytial virus during their first RSV season, the ...

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

Merck (MRK) stock is in focus as its Enflonsia RSV shot is cleared for infants in the U.S. in a market led by Sanofi (SNY) ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 cause of hospitalization in infants.

One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...

Merck & Co., Inc. (NYSE:MRK) is one of the best wide moat stocks to buy now. On June 9, Merck’s preventative antibody shot ...

Merck’s Enflonsia will go up against Sanofi and AstraZeneca’s Beyfortus, which the partners plan to ship out early in the ...